Join
Live feed
·
PRReleasevia Quantisnow
Mirum Pharmaceuticals Inc. logo

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

ByQuantisnow·Wall Street's wire, on your screen.
MIRM· Mirum Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIRM (Mirum Pharmaceuticals Inc.) and more on Quantisnow.